Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.

in addition to its existing use for assessing HER2-low status. The FDA's expansion of the diagnostic's label comes after Enhertu (trastuzumab deruxtecan), an HER2-targeting antibody-drug conjugate ...

The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.

There are no targeted therapies specifically approved for patients with HER2-ultra-low expression, and approval would move Enhertu up the treatment pathway ahead of chemo. The results reported at ...

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

India's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

AstraZeneca PLC (LON:AZN:LN) (NASDAQ: AZN), a pharmaceutical giant with a market capitalization of $224.5 billion, received a new Overweight rating from Morgan Stanley (NYSE:MS), accompanied by a ...

Jazz is also advancing zanidatamab in combo with chemo or chemo and trastuzumab in a Phase 3 trial (HER-BC-303) as a treatment for HER2+ breast cancer where disease has progressed on Enhertu and ...